LiDCO Group Plc announced that the company's latest cardiac output monitor with non-invasive technology has received regulatory approval for commercial sale in China. The Chinese Food and Drug Administration (CFDA) has formally approved the company's hemodynamic LiDCOrapidv3 monitor product for commercial sale in China and it will be sold via LiDCO's distribution partner, Beijing Gloryway Medical Co. Ltd. China is the second larger healthcare market in the world with a five-year compound annual growth rate by value of 17% compared with 4% in the United States. Over the last few years an increasing number of clinical studies originating from China have been published reinforcing the positive impacts of hemodynamic monitoring and as a result this has led to increasing adoption of hemodynamic monitoring technologies. LiDCO, through its distribution partner, had built a significant business before regulatory restrictions to a key component in 2017 limited sales. With this approval, these restrictions no longer apply and the Board anticipates that Gloryway will re-launch the LiDCO offering with renewed vigour in the second half of 2019.